Glucosil: advanced OTC respiratory therapeutic treatment
Glucosil is a groundbreaking OTC respiratory therapy combining silver and glucosamine to create a biostatic, antimicrobial barrier. It offers prolonged protection against infections and inflammation, suitable for use via nasal spray, inhaler, or gel.
Overview
Glucosil represents a novel over-the-counter (OTC) respiratory therapeutic treatment that leverages a patented process to bind silver to amines of glucosamine. This innovative formulation releases minimal silver (around 4 ppb) while providing a biostatic, mucoadhesive, anti-inflammatory, hypoallergenic, and antimicrobial barrier. Designed for administration as a nasal spray, aerosol, or gel, Glucosil forms a thin, flexible, semi-permanent barrier over mucosal cells. This barrier captures dust, debris, viruses, bacteria, and fungal irritants, effectively neutralizing threats and preventing infections and inflammation for several hours.
Technical specifications
- Composition: Glucosamine and silver, utilizing a patented binding process
- Properties: Biostatic, mucoadhesive, anti-inflammatory, hypoallergenic, antimicrobial
- Forms: Nasal spray, aerosol, gel
- Application: Can be administered easily by elderly and children; suitable for use with nasal sprays, puff inhalers, nebulizers, or as a nasal gel
- Safety: Ingredients recognized as GRAS (Generally Recognized As Safe); no harm to microbiome expected
- Cultural Compliance: Can be made with mushroom chitosan for kosher and halal approval
Technology readiness level
Glucosil is currently at Technology Readiness Level (TRL) 4, indicating that it has been validated in a laboratory environment. The next steps involve discussions with the FDA to determine additional studies required for regulatory approval as an OTC product. A 510k application and further research will be pursued to address any gaps and achieve market readiness.
About Chitozan Health LLC
Chitozan Health LLC is a biotechnology research firm that develops antimicrobial solutions utilizing patented silver-chitosan technology [1][3][5]. Their core innovation, marketed as Silver Shell or Glucosil, incorporates chitosan and silver particles to create durable, effective antimicrobial barriers for various applications [1][5][8]. By leveraging the biostatic properties of chitosan, the company produces textile finishes and topical gels that are designed to combat pathogens, including bacteria, fungi, and viruses, while minimizing the use of silver and maintaining safety standards [1][5][8]. This research is supported by NIH NIAID funding and focuses on managing infections, such as those related to Pseudomonas aeruginosa in cystic fibrosis, as well as providing broad-spectrum protection in healthcare and consumer settings [1][5][7].
These products serve a range of stakeholders, from industrial partners in textile manufacturing and sustainable packaging to healthcare providers and individual consumers in need of advanced wound and burn care [1][4][7][8]. The company's technology addresses critical challenges such as antimicrobial resistance, infection control, and the environmental impact of synthetic materials [1][4][8]. Through rigorous independent laboratory testing, their treatments have demonstrated significant efficacy in reducing pathogen populations and sustaining performance even after multiple commercial wash cycles [1][5]. With a focus on sustainable, naturally derived materials, Chitozan Health aims to provide safer, more effective alternatives for infection mitigation across multiple sectors [1][7].
delivered to your inbox.